(PDF) P3.01-63 Baseline Biomarkers for Outcome of Advanced

P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1623

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology

Respiratory Medicine

English

PD-L1 Expression in Advanced NSCLC: Insights Into Risk Stratification and Treatment Selection From a Systematic Literature Review

Cancer Research

Respiratory Medicine

English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology

Respiratory Medicine

English

Long-Term Survival in Patients Responding to Anti-Pd-1/Pd-L1 Therapy and Disease Outcome Upon Treatment Discontinuation

Clinical Cancer Research

Cancer Research

English

P2.04-17 Pre-Therapy Radiomic Features Can Distinguish Hyperprogression From Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Neutrophil Content Predicts Lymphocyte Depletion and Anti-Pd1 Treatment Failure in NSCLC

English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English